Mapping the gap: scoping review protocol on medication safety and adverse reactions in dental practice
DOI:
https://doi.org/10.62741/ahrj.v3iSuppl.142Keywords:
dentistry, adverse drug reactions, pharmacovigilance, prevalence, dental treatmentAbstract
Introduction: Adverse drug reactions are a relevant yet frequently underreported concern in dental practice, particularly regarding their prevalence and association with commonly prescribed medications such as antibiotics, analgesics, and anti-inflammatory drugs.
Objectives: The aim is to systematically map adverse drug reactions in dental practice, identifying implicated drugs, reported reactions, and current reporting practices.
Methodology: A scoping review will be conducted in accordance with the Joanna Briggs Institute methodology. Scientific databases and grey literature will be searched using the following keywords: adverse drug reactions, pharmacovigilance, dentistry, prevalence, and dental treatment.
Results: This scoping review will include studies aligned with the defined objective, aiming to map the existing evidence on the prevalence of adverse drug reactions in dental practice and the medications most commonly associated with them. This study will synthesize global evidence on adverse drug reactions in dental practice, will highlight underreporting, gaps in awareness and
training, and regional variability, and will propose educational, curricular, digital, and interdisciplinary strategies to strengthen pharmacovigilance, improve prescribing safety, and enhance patient safety in dentistry.
Conclusion: The findings of this scoping review will support safer prescribing practices in dentistry and contribute to a better understanding of pharmacovigilance within dental care settings.
References
Teoh L, Moses G, McCullough MJ. A review and guide to drug-associated oral adverse effects—dental, salivary and neurosenso-ry reactions. Part 1. J Oral Pathol Med. 2019;48(7):626-636. doi:10.1111/jop.12911 DOI: https://doi.org/10.1111/jop.12911
Madhushika MT, Weerarathna TP, Liyanage PLGC, et al. Evolu-tion of adverse drug reactions reporting systems: paper based to software based. Eur J Clin Pharmacol. 2022;78(9):1385-1390. doi:10.1007/s00228-022-03358-3 DOI: https://doi.org/10.1007/s00228-022-03358-3
Parracha ER, Advinha AM, Lopes MJ, et al. Mobile apps for quick adverse drug reaction report: a scoping review. Pharmacoepi-demiol Drug Saf. 2023;32(1):19-27. doi:10.1002/pds.5542 DOI: https://doi.org/10.1002/pds.5542
Trenque A, Rabiaza A, Fedrizzi S, et al. Evaluation of a simplified pharmacovigilance tool for general practitioners: 5 years of in-sight. Sci Rep. 2024;14:1766. doi:10.1038/s41598-024-51753-w DOI: https://doi.org/10.1038/s41598-024-51753-w
Thornhill MH, Dayer MJ, Durkin MJ, et al. Risk of adverse reac-tions to oral antibiotics prescribed by dentists. J Dent Res. 2019;98(10):1081-1087. doi:10.1177/0022034519863645 DOI: https://doi.org/10.1177/0022034519863645
Ferreira-da-Silva R, Ribeiro-Vaz I, Silva AM, et al. Retrospectiva de 20 anos de atividade da Unidade de Farmacovigilância do Por-to, Portugal. Cad Saude Publica. 2021;37(10):e00304420. doi:10.1590/0102-311X00304420 DOI: https://doi.org/10.1590/0102-311x00304420
Pearson A, Wiechula R, Court A, et al. The JBI model of evidence-based healthcare. Int J Evid Based Healthc. 2005;3(8):207-215. doi:10.1111/j.1479-6988.2005.00026.x DOI: https://doi.org/10.1111/j.1479-6988.2005.00026.x
Pearson A, Jordan Z, Munn Z. Translational science and evidence-based healthcare: a clarification and reconceptualization of how knowledge is generated and used in healthcare. Nurs Res Pract. 2012;2012:792519. doi:10.1155/2012/792519 DOI: https://doi.org/10.1155/2012/792519
Jordan Z, Lockwood C, Munn Z, et al. The updated Joanna Briggs Institute model for evidence-based healthcare. Int J Evid Based Healthc. 2019;17:58-71. doi:10.1097/XEB.0000000000000155 DOI: https://doi.org/10.1097/XEB.0000000000000155
McGowan J, Sampson M, Salzwedel DM, et al. PRESS peer re-view of electronic search strategies: 2016 guideline statement. J Clin Epidemiol. 2016;75:40-46. doi:10.1016/j.jclinepi.2016.01.021 DOI: https://doi.org/10.1016/j.jclinepi.2016.01.021
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic re-views. BMJ. 2021;372:n71. doi:10.1136/bmj.n71 DOI: https://doi.org/10.1136/bmj.n71
Soto J, Meyer M. Oral implications of polypharmacy in older adults. J Gerodontol. 2023;40(2):123-130. doi:10.1111/ger.12644 DOI: https://doi.org/10.1016/j.cger.2023.01.008
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Athena Health & Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of published papers is assigned to the Journal, but all content is licensed under the terms of Creative Commons Non-comercial 4.0 International License. Thus users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
